Trial Profile
Cessation versus continuation of 12 months galantamine therapy in patients with Alzheimer's disease: a randomised, double blind, placebo controlled withdrawal trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2011
Price :
$35
*
At a glance
- Drugs Galantamine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 04 Aug 2011 New trial record